Literature on antiepileptic-induced iatrogenic hyperglyceamia is scanty. Due to its broad spectrum of activity and mechanisms of action, valproic acid (VPA), a fatty acid, is one of the most widely prescribed epilepsy treatments worldwide. Herein, we describe an adolesent epileptic patient, in whom persistent, otherwise unexplained, hyperglyceamia was most likely induced by VPA, as suggested by the VPA and glucose blood level normalcy after withdrawal. Indeed, no further hyperglyceamic episodes occurred after VPA discontinuation. This case supports the hypothesis that VPA may induce hyperglyceamia, due to still not well-defined metabolic mechanisms of action. Moreover, this emphasizes the need for more monitoring on paediatric patients on this medication, so as to be forestall complications, if it may arise.